The 2026 LiBBY trial does not establish routine THC-CBD care for mild cognitive impairment because it enrolled only hospice-eligible people with advanced dementia and severe agitation. It measured short-term agitation relief, not memory, daily function, or progression from MCI to dementia. MCI means measurable thinking decline without loss of independence in daily life. LiBBY tested a different problem, in different patients, with an investigational drug that still needs larger trials.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who took part in LiBBY?
- What improved, and what was not tested?
- Why doesn't one positive trial change routine care?
- What should people with MCI discuss instead?
Who took part in LiBBY?
LiBBY was a 12-week Phase 2 randomized placebo-controlled trial in 120 people with Alzheimer's or other dementia plus major agitation. According to the Alzheimer's Association, topline results were first presented at AAIC 2026 in London AAIC meeting release. Participants were hospice-eligible with severe, late-stage disease.
People with MCI were not included. MCI keeps independence in daily activities, while these patients needed end-of-life care. The treatment was T2:C100, a proprietary oral capsule with 2 mg THC plus 100 mg CBD taken twice daily versus placebo. MediPharm Labs reports it supplied the formulation for the NIA-funded ACTC trial company results announcement.
What improved, and what was not tested?
Treated patients had a 6.27-point larger drop than placebo on the Cohen-Mansfield Agitation Inventory at week 2. That scale rates restlessness, pacing, shouting, and physical aggression. Clinician-rated improvement reached 87.2% on treatment versus 23.6% on placebo at week 12.
The goal was less distress and fewer disruptive behaviors in advanced dementia. LiBBY did not test MCI care. It did not measure slower decline to dementia, better recall, or sharper planning. A calm hospice patient is a different outcome from a person with MCI staying independent longer.
Why doesn't one positive trial change routine care?
Phase 2 trials test signals, not standard practice. LiBBY was small, brief, and reported as topline conference findings, so results can shift after full peer review. Safety also needs larger study.
According to NeurologyLive, overall adverse events were similar at 46.7% versus 42.4%, but serious events were 23.3% versus 11.9% and deaths were 13.1% versus 5.1% trial safety coverage. Investigators judged them unrelated, yet frail hospice patients have high background risk. The T2:C100 product remains investigational and is not FDA-approved for dementia agitation. The first and only FDA-approved drug for agitation in Alzheimer's dementia is brexpiprazole, approved in May 2023.
What should people with MCI discuss instead?
Do not apply hospice agitation results to early memory concerns. Older adults clear cannabis more slowly and face higher risks of confusion, dizziness, falls, and drug interactions.
Bring cannabis questions to the regular clinician or pharmacist. A practical visit checklist helps: Families can track triggers, daily function, and side effects between visits. For MCI, proven steps are treat vascular risks, review sedating drugs, protect sleep, stay active, and plan repeat cognitive checks.
- list memory symptoms, sleep, mood, falls, and driving concerns
- list all prescriptions, sleep aids, pain drugs, alcohol, and supplements
- ask about blood pressure, memory testing, hearing, sleep apnea, and medication review
- ask what agitation plan fits advanced dementia, separate from MCI follow-up
You Might Also Like
- Physical Activity in the 2026 WHO Dementia Guideline: How the Advice Compares With Common Online Claims for Adults Over 65
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: A Source-Checked Research Briefing for Family Caregivers
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: A Source-Checked Research Briefing for Family Caregivers
